Article
CYP2D6 testing in breast cancer: ready for prime time?
Oncology (Williston Park, N.Y.) - 1 Dec 2009
Kuderer Nicole M, Peppercorn Jeffrey
Abstract excerpt
Despite recent advances in hormonal therapy for breast cancer, tamoxifen remains a major therapeutic option, with indications ranging from primary prevention to metastatic disease. Understanding the variation in response to tamoxifen may significantly improve our ability to personalize cancer care and maximize therapeutic efficacy. One area of particular interest is the impact of cytochrome P450 CYP2D6 genetic...
Topics
Join the communities discussing this publication.